Alnylam: 2Q Earnings Snapshot
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Tuesday reported a loss of $219.5 million in its second quarter.
The Cambridge, Massachusetts-based company said it had a loss of $2.02 per share. Losses, adjusted for one-time gains and costs, were $1.83 per share.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.81 per share.
The RNA interference drug developer posted revenue of $44.7 million in the period, also falling short of Street forecasts. Five analysts surveyed by Zacks expected $47.3 million.
Alnylam shares have declined 2% since the beginning of the year. The stock has dropped 22% in the last 12 months.